{"filings":[{"id":94128,"accession_number":"0001619856-26-000035","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.","Cash and marketable securities $118.6M as of Mar 31, 2026; expected to fund into 2H 2027.","R&D expenses down to $20.6M from $35.5M; G&A down to $8.1M from $9.7M YoY.","CB-011 granted RMAT for r/r MM; enrollment ongoing, dose expansion data expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2397000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106275,"accession_number":"0001619856-26-000012","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.","RMAT based on CaMMouflage phase 1 dose escalation data: 92% ORR, 75% ≥CR, 91% MRD negativity in 12 BCMA-naïve patients at RDE.","No graft-versus-host disease or certain neurotoxicities observed; manageable safety profile reported.","Dose expansion enrollment ongoing for both BCMA-naïve and BCMA-exposed cohorts; additional data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106274,"accession_number":"0001619856-26-000007","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.","Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.","Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.","Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.","CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122584,"accession_number":"0001619856-25-000070","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).","CB-011 CaMMouflage phase 1: 92% ORR, 75% ≥CR, 91% MRD-negativity in 12 BCMA-naïve patients at recommended dose.","Cash, equivalents, and marketable securities $159.2M as of Sep 30, 2025; expected to fund operations into 2H 2027.","Q3 2025 revenue $2.2M (vs $2.0M Q3 2024); R&D expenses $22.4M (down from $30.4M); G&A $9.2M (down from $9.8M).","FDA recommends randomized controlled trial for vispa-cel pivotal phase 3 in 2L LBCL; company to refine design with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":7218000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122583,"accession_number":"0001619856-25-000065","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.","Optimized profile cohort (N=35): 86% ORR, 63% CR rate, 53% 12-month PFS; median follow-up 11.8 months.","CB-011 (BCMA) dose escalation: 92% ORR, 75% CR/sCR at RDE (450M cells) in BCMA-naïve r/r MM; dose expansion by end 2025.","Planned pivotal phase 3 for vispa-cel in 2L LBCL: FDA recommends randomized controlled trial, ~250 patients, PFS primary endpoint.","Preliminary cash, equivalents, and marketable securities as of Sep 30, 2025: approximately $159.2 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139269,"accession_number":"0001619856-25-000060","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.","Cash $183.9M as of June 30, down from $249.4M at Dec 31; expected to fund operations into H2 2027.","Completed enrollment of 20-patient confirmatory cohort for CB-010 in 2L LBCL; data and pivotal trial plans expected H2 2025.","Completed dose escalation enrollment for CB-011 CaMMouflage trial in r/r MM; dose expansion data expected H2 2025.","R&D expenses fell to $27.7M from $35.5M due to pipeline prioritization and workforce reduction; G&A down to $10.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5020000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156841,"accession_number":"0001619856-25-000052","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Caribou Biosciences regains Nasdaq minimum bid price compliance after 10-day period above $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq compliance notice on June 18, 2025, confirming regained compliance with Listing Rule 5450(a)(1).","Closing bid price was $1.00 or greater for 10 consecutive trading days from June 3 to June 17, 2025.","Company had been at risk of delisting due to bid price deficiency; notice resolves that risk.","Company's common stock remains listed on the Nasdaq Global Select Market under ticker CRBU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156840,"accession_number":"0001619856-25-000047","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Caribou Biosciences stockholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors elected: Scott Braunstein (40.2M votes for) and Ran Zheng (30.4M votes for).","Deloitte & Touche ratified as independent auditor for FY2025 (66.5M for, 1.1M against).","Amendment to charter approved to allow reverse stock split at ratio from 1:5 to 1:50, as determined by board.","Adjournment proposal approved but unnecessary due to quorum and sufficient votes on all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156839,"accession_number":"0001619856-25-000040","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).","Net loss $40.0M vs $41.2M YoY; R&D expenses $35.5M (up from $33.8M) and G&A $9.7M (down from $14.6M).","Discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical work; workforce reduced ~32% with $2.5–3.5M cash costs.","CB-010 (2L LBCL) and CB-011 (multiple myeloma) Phase 1 data expected in H2 2025 with FDA interaction for potential pivotal trial.","Licensing revenue flat at $2.4M for the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2353000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156838,"accession_number":"0001619856-25-000023","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.","Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.","Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.","Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.","Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175249,"accession_number":"0001619856-25-000014","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.","Cash, equivalents & marketable securities $249.4M at Dec 31, 2024, funding operations into H2 2026.","CB-010 ANTLER and CB-011 CaMMouflage Phase 1 clinical data expected in H1 2025.","CSO Steve Kanner to retire end of June 2025; no replacement planned; functions split among execs.","CFO Sri Ryali appointed in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175248,"accession_number":"0001619856-25-000006","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.","CB-010 ANTLER and CB-011 CaMMouflage Phase 1 data expected H1 2025; CB-010 pivotal Phase 3 planned H2 2025 pending HLA matching.","CB-012 AMpLify Phase 1 in r/r AML: dose level 3 completed with no DLTs; enrolling dose level 4.","Sri Ryali appointed CFO; $281M cash expected to fund operations into H2 2026.","CB-012 granted FDA Fast Track and Orphan Drug designation for r/r AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175247,"accession_number":"0001619856-25-000002","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Caribou Biosciences appoints Sri Ryali as CFO, effective January 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sri Ryali named CFO; brings 20 years biopharma finance experience; most recently CFO of Codexis.","Ryan Fischesser ceases as interim principal financial officer and accounting officer; remains VP Finance.","Ryali receives $485k base salary, 40% target bonus, and option to purchase 300k shares vesting over 4 years.","Company highlights four clinical-stage programs for hematologic malignancies and autoimmune diseases; expects multiple datasets in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192194,"accession_number":"0001619856-24-000080","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.","Cash & equivalents $281M as of Sept 30, 2024, down from $372.4M at Dec 31, 2023.","CB-010 lupus GALLOP Phase 1 trial initiation expected by year-end 2024; Fast Track granted.","CB-011 CaMMouflage dose escalation data for r/r MM expected H1 2025; no DLTs observed.","Tina Albertson, MD/PhD, appointed CMO in August 2024; led BREYANZI development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":7917000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208679,"accession_number":"0001619856-24-000074","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K/A","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Caribou Biosciences appoints Ryan Fischesser interim CFO and grants 25,000 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Fischesser designated interim principal financial officer and accounting officer effective Sept 27, 2024, following Jason O'Byrne's resignation.","Fischesser to receive 25,000 RSUs on Nov 20, 2024, vesting fully on Nov 20, 2025, subject to continued employment.","The original 8-K filed Sept 3, 2024 reported O'Byrne's resignation; this amendment supplements compensatory terms.","Fischesser previously served as VP of Finance and Controller."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208683,"accession_number":"0001619856-24-000071","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Jason O'Byrne resigns effective Sept 27; Ryan Fischesser named principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason O'Byrne resigns as CFO effective Sept 27, 2024, to pursue other opportunity; no disagreement with company.","Company has initiated search for new CFO.","Ryan Fischesser, VP Finance and Controller, will assume principal accounting officer role Sept 27.","Fischesser previously served as principal accounting officer from IPO through Dec 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208682,"accession_number":"0001619856-24-000068","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.","At Juno Therapeutics (BMS), she led global development of BREYANZI from IND to BLA filing and FDA approval.","She will oversee clinical, regulatory, and medical affairs for Caribou's four CAR-T cell therapy programs.","Dr. Albertson reports to CEO Rachel Haurwitz and will drive allogeneic CAR-T development in hematologic and autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208681,"accession_number":"0001619856-24-000063","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.","Discontinued preclinical CAR-NK platform; reduced workforce ~12% to extend cash runway into H2 2026.","CB-010 ANTLER enrolling ~20 2L LBCL and ~10 prior CD19 relapsed patients; initial data expected H1 2025.","CB-011 CaMMouflage dose-escalation data for r/r multiple myeloma planned by year-end 2024.","Appointed autoimmune expert Terri Laufer, MD to SAB; CB-010 GALLOP lupus trial initiation expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":5893000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208680,"accession_number":"0001619856-24-000054","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.","Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.","Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.","Estimated severance costs $0.5M–$1.0M in Q3 2024.","Cash runway extended at least 6 months into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226408,"accession_number":"0001619856-24-000050","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Caribou Biosciences stockholders elect three directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors: Rachel Haurwitz (57.4M for), Dara Richardson-Heron (50.2M for), Natalie Sacks (50.2M for).","Ratified Deloitte & Touche as independent auditor for FY 2024 with 73.0M votes for, 0.2M against.","Broker non-votes of 13.6M shares on director elections; no broker votes on auditor ratification.","Annual meeting held June 13, 2024; all proposals passed as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226407,"accession_number":"0001619856-24-000046","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).","In LBCL patients with ≥4 HLA matches (N=11), median PFS not reached; ORR 91%, CR rate 36%.","No Grade ≥3 CRS or GvHD observed; RP2D selected at 80x10^6 CAR-T cells.","Plan to enroll ~20 additional 2L LBCL patients prospectively; initial data expected H1 2025.","Pivotal Phase 3 trial for CB-010 in 2L LBCL planned for H2 2025 if confirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226406,"accession_number":"0001619856-24-000036","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.","Cash, cash equivalents, and marketable securities $345.9M as of Mar 31, 2024, funding operations into Q1 2026.","FDA IND clearance for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 trial expected to start by YE 2024.","Plans to present initial CB-010 dose expansion data at ASCO June 3, 2024; initial CB-011 data by YE 2024.","Licensing and collaboration revenue $2.4M, down from $3.5M due to terminated AbbVie agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":2429000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226405,"accession_number":"0001619856-24-000018","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Caribou Biosciences receives FDA IND clearance for CB-010 in lupus; GALLOP Ph1 trial expected by YE 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.","Phase 1 GALLOP trial expected to initiate by year-end 2024; evaluates safety of single infusion with partial HLA matching.","CB-010 clinical development expanded from oncology to autoimmune diseases; driven by encouraging initial ANTLER trial data in r/r B-NHL.","Caribou reports $372.4M cash as of Dec 31, 2023, expected to fund operations into Q1 2026.","Initial dose expansion data from ANTLER Phase 1 trial for 2L LBCL to be presented at a medical congress in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245425,"accession_number":"0001619856-24-000012","cik":1619856,"company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.","Cash, equivalents, and marketable securities $372.4M at Dec 31, 2023, up from $317.0M; expected to fund operations into Q1 2026.","CB-010: 30th patient dosed in ANTLER dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024.","CB-012: First patient dosed in AMpLify Phase 1 trial for r/r AML.","CB-020 preclinical anti-ROR1 CAR-NK program paused; CB-011 enrollment continues at dose level 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230594842.6623377,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}